Last updated: May 28, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06324357 | 1, 2 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | HER2 -- tyrosine kinase inhibitor and antibody-drug conjugates |
| NCT02422641 | 2 | Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis | Dihydrofolate reductase -- high-dose methotrexate (antimetabolite chemotherapy) |
| NCT06631092 | 1, 2 | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer | Tumor neoantigens -- personalized DNA vaccine |
| NCT07426913 | — | Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab | Unknown mechanism |
| NCT07237256 | 3 | Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib | CDK4/6 -- kinase inhibitor (CDK4/6 inhibitor) |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 106 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 39 |
| Memorial Sloan Kettering Cancer Center | 34 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 29 |
| The First Affiliated Hospital with Nanjing Medical University | 28 |
Countries/regions with the most active trial sites for breast cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Oct 1, 2026 | NCT07553390 | Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers | TGFBR2 -- knockout; TROP2 -- chimeric antigen receptor (CAR) NK cells; HER2 -- antibody-drug conjugate (trastuzumab deruxtecan) |
| Sep 2026 | NCT07545122 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers | Nectin-4 -- bispecific antibody (CT-202) |
| Jul 3, 2026 | NCT07601620 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer | HER2 -- monoclonal antibody (HLX319, biosimilar to Phesgo) |
| Jul 1, 2026 | NCT07494448 | Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer | HER2 -- bispecific antibody plus HER2 tyrosine kinase inhibitor |
| Jul 2026 | NCT07136428 | Asciminib in HER2+ Breast Cancer Brain Metastases | BCR-ABL allosteric site -- allosteric inhibitor + HER2 -- monoclonal antibody |
| Jun 30, 2026 | NCT07300475 | Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients | PD-1 + chemotherapy agents -- immune checkpoint inhibitor + chemotherapy |
| Jun 15, 2026 | NCT06148038 | CBD for Breast Cancer Primary Tumors | Cannabinoid receptor -- cannabinoid receptor agonist (CBD) |
| Jun 2026 | NCT06949410 | HER2 Vaccine for Locally Advanced Breast Cancer | HER2 -- therapeutic vaccine |
You've seen the breast cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.